Home
/ Trethera

Trethera

Trethera

Total Funding

$7.4 M

Trethera Summary

Company Summary

Overview: Trethera is a preclinical-stage biopharmaceutical company developing cancer treatments. It focuses on the pathways controlling cancer nucleotide metabolism and offers TRE-515, an inhibitor of deoxycytidine kinase (dCK).

Type: Private

Status: Active

Founded: 2013

HQ: Los Angeles, CA, US | view all locations

Website: http://trethera.com/

Cybersecurity rating

Sectors

Table of Contents

Locations
Competitors
News
Blogs

LocationsView all

1 location detected

Los Angeles, CA HQ
United States
13547 Ventura Blvd #363, Sherman Oaks

Competitors and Similar Companies

Compare competitors

News

Trethera Announces Appointment of Laurent Dubois to Board of Directors

Feb 15, 2023

Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors

Jan 18, 2023

Trethera Receives $1.6 Million National Eye Institute Grant for Continued Advancement of TRE-515 Optic Neuritis Program

Oct 19, 2022

Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting

Oct 4, 2022

Blogs

Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Jan 24, 2023

Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022

May 19, 2022

Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors

May 12, 2022

Trethera Announces Prostate Cancer Poster Presentation at the American Association for Cancer Research Annual Meeting

Mar 22, 2022

Footer menu

Product

Solutions

Resources

Company

© Craft.co 2024

Share price data provided by IEX